Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter "X-TRA"

Completed

Phase 3 Results N/A

Update History

15 Nov '14
A location was updated in Plovdiv.
New
The overall status was removed for Name Unavailable.
A location was updated in Sofia.
New
The overall status was removed for Name Unavailable.
A location was updated in Sofia.
New
The overall status was removed for Name Unavailable.
A location was updated in Varna.
New
The overall status was removed for Name Unavailable.
A location was updated in Creteil.
New
The overall status was removed for Name Unavailable.
A location was updated in Marseille.
New
The overall status was removed for Name Unavailable.
A location was updated in Paris.
New
The overall status was removed for Name Unavailable.
A location was updated in TOULOUSE cedex.
New
The overall status was removed for Name Unavailable.
A location was updated in Bonn.
New
The overall status was removed for Name Unavailable.
A location was updated in Leipzig.
New
The overall status was removed for Name Unavailable.
A location was updated in Berlin.
New
The overall status was removed for Name Unavailable.
A location was updated in Hamburg.
New
The overall status was removed for Name Unavailable.
A location was updated in Krakow.
New
The overall status was removed for Name Unavailable.
A location was updated in Lodz.
New
The overall status was removed for Name Unavailable.
A location was updated in Lublin.
New
The overall status was removed for Name Unavailable.
A location was updated in Warszawa.
New
The overall status was removed for Name Unavailable.
A location was updated in Warszawa.
New
The overall status was removed for Name Unavailable.
A location was updated in Wroclaw.
New
The overall status was removed for Name Unavailable.
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
A location was updated in Saratov.
New
The overall status was removed for Name Unavailable.
A location was updated in St. Petersburg.
New
The overall status was removed for Name Unavailable.
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
A location was updated in Samsun.
New
The overall status was removed for Name Unavailable.
A location was updated in Donetsk.
New
The overall status was removed for Name Unavailable.
A location was updated in Kiev.
New
The overall status was removed for Name Unavailable.
A location was updated in Odesa.
New
The overall status was removed for Name Unavailable.
A location was updated in Uzhhorod.
New
The overall status was removed for Name Unavailable.
21 Oct '14
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
19 Sep '14
A location was updated in Bonn.
New
The overall status was removed for Name Unavailable.
A location was updated in Leipzig.
New
The overall status was removed for Name Unavailable.
A location was updated in Hamburg.
New
The overall status was removed for Name Unavailable.
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
13 Aug '14
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
A location was updated in St. Petersburg.
New
The overall status was removed for Name Unavailable.
11 Jul '14
A location was updated in Bonn.
New
The overall status was removed for Name Unavailable.
18 Apr '14
The eligibility criteria were updated.
New
Inclusion Criteria: - Men or women aged >/= 18 years - Hemodynamically stable nonvalvular AF or atrial flutter - LA/LAA thrombus documented at baseline by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication - vitamin K antagonist(s) (VKA)/ new oral anticoagulant(s) (NOAC)-naïve or untreated within 1 month prior to signing of the informed consent form - VKA pretreated but under ineffective INR levels(<2.0,documented with at least 2 consecutive measurements that are at least 24 hours apart) within last 6 weeks - Women of childbearing potential and men must agree to use adequate contraception when sexually active Exclusion Criteria: - Transient Ischemic Attack within 3 days prior to study inclusion - Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug - Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion - Acute myocardial infarction within the last 14 days prior to study inclusion - Cardiac-related criteria: Previous intracardiac thrombus, Free-floating ball thrombus, Intracardiac tumor, known left ventricular or aortic thrombus - Active bleeding or high risk for bleeding contraindicating anticoagulant therapy - Concomitant drugs/therapies: Indication for anticoagulant therapy for a condition other than nonvalvular AF or atrial flutter (eg, venous thromboembolism). Concomitant use of anticoagulant drugs, including VKA, or factor IIa or factor Xa inhibitors. Chronic aspirin therapy >100 mg or dual antiplatelet therapy. Concomitant use of strong inhibitors of both cytochrome P450 (CYP) 3A4 and P glycoprotein (P-gp), ie, all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents—ketoconazole, itraconazole, voriconazole, and posaconazole—if used systemically - Concomitant conditions: Childbearing potential without proper contraceptive measures, pregnancy, or breast feeding. Hypersensitivity to investigational treatment. Calculated creatinine clearance (CrCl) < 15 mL/minute at the screening visit. Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk. Any severe condition that would limit life expectancy to less than 3 months (eg, advanced malignancy, etc.). Planned invasive procedure with potential for uncontrolled bleeding or increased risk of stroke, including major surgery, cardiac catheterization, or cardioversion prior to the end-of-treatment TEE. Inability to take oral medication. Ongoing drug addiction or alcohol abuse
Old
Inclusion Criteria: - Men or women aged >/= 18 years - Hemodynamically stable nonvalvular AF or atrial flutter - LA/LAA thrombus documented at baseline by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication - vitamin K antagonist(s) (VKA)/ new oral anticoagulant(s) (NOAC)-naïve or untreated within 1 month prior to signing of the informed consent form - Women of childbearing potential and men must agree to use adequate contraception when sexually active Exclusion Criteria: - Transient Ischemic Attack within 3 days prior to study inclusion - Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug - Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion - Acute myocardial infarction within the last 14 days prior to study inclusion - Cardiac-related criteria: Previous intracardiac thrombus, Free-floating ball thrombus, Intracardiac tumor, known left ventricular or aortic thrombus - Active bleeding or high risk for bleeding contraindicating anticoagulant therapy - Concomitant drugs/therapies: Indication for anticoagulant therapy for a condition other than nonvalvular AF or atrial flutter (eg, venous thromboembolism). Concomitant use of anticoagulant drugs, including VKA, or factor IIa or factor Xa inhibitors. Chronic aspirin therapy >100 mg or dual antiplatelet therapy. Concomitant use of strong inhibitors of both cytochrome P450 (CYP) 3A4 and P glycoprotein (P-gp), ie, all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents—ketoconazole, itraconazole, voriconazole, and posaconazole—if used systemically - Concomitant conditions: Childbearing potential without proper contraceptive measures, pregnancy, or breast feeding. Hypersensitivity to investigational treatment. Calculated creatinine clearance (CrCl) < 15 mL/minute at the screening visit. Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk. Any severe condition that would limit life expectancy to less than 3 months (eg, advanced malignancy, etc.). Planned invasive procedure with potential for uncontrolled bleeding or increased risk of stroke, including major surgery, cardiac catheterization, or cardioversion prior to the end-of-treatment TEE. Inability to take oral medication. Ongoing drug addiction or alcohol abuse
28 Mar '14
A location was updated in Creteil.
New
The overall status was removed for Name Unavailable.
A location was updated in Uzhhorod.
New
The overall status was removed for Name Unavailable.
1 Mar '14
A location was updated in Krakow.
New
The overall status was removed for Name Unavailable.
A location was updated in Lublin.
New
The overall status was removed for Name Unavailable.
31 Jan '14
A location was updated in Wroclaw.
New
The overall status was removed for Name Unavailable.
A location was updated in Moscow.
New
The overall status was removed for Name Unavailable.
A location was updated in Kiev.
New
The overall status was removed for Name Unavailable.
4 Jan '14
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
A location was updated in Istanbul.
New
The overall status was removed for Name Unavailable.
A location was updated in Donetsk.
New
The overall status was removed for Name Unavailable.
4 Dec '13
A location was updated in Plovdiv.
New
The overall status was removed for Name Unavailable.
A location was updated in Varna.
New
The overall status was removed for Name Unavailable.
A location was updated in Samsun.
New
The overall status was removed for Name Unavailable.
1 Nov '13
A location was updated in Lodz.
New
The overall status was removed for Name Unavailable.
30 Aug '13
A location was updated in Sofia.
New
The overall status was removed for Name Unavailable.